Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02756390 · ClinicalTrials.gov registry record · NA

CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors

A NA study of Insomnia, sponsored by Dana-Farber Cancer Institute.

Completed
Registry status
NA
Development phase
56
Enrollment target
1
Study location

NCT02756390: Completed NA study of Insomnia, sponsored by Dana-Farber Cancer Institute.

NCT02756390 is a NA study of Insomnia that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 56 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (67% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02756390, a NA study of Insomnia, has completed, sponsored by Dana-Farber Cancer Institute.

COMPLETED
Registry status
NA
Development phase
56 participants
Enrollment target
1
Study location

Study Summary

This research study is evaluating the effectiveness of a 3-session behavioral intervention for insomnia in cancer survivors. This is a behavioral intervention study, and no medications are involved.

Primary Outcome

The ISI is a 7-item self-report questionnaire assessing severity, and impact of insomnia symptoms.

Conditions Studied

Interventions

  • BEHAVIORAL Sleep Hygiene
  • BEHAVIORAL CBTI-CS
  • BEHAVIORAL CBTI-CS via Telehealth

Study Locations (1)

Massachusetts

  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2015-12
Est. Completion 2018-05-14
Phase NA
Dana-Farber Cancer Institute

781 total trials

What the finished NCT02756390 record still lists

NCT02756390 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (67% lower).

The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 3 interventions - of which Sleep Hygiene is the first listed.

NCT02756390 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT02756390 about?

NCT02756390 is a clinical study titled "CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors". This research study is evaluating the effectiveness of a 3-session behavioral intervention for insomnia in cancer survivors. This is a behavioral intervention study, and no medications are involved.

What is the current status of trial NCT02756390?

This trial is currently completed. It is a NA study. The enrollment target is 56 participants. The study started on 2015-12. Estimated completion is 2018-05-14.

What conditions does trial NCT02756390 study?

This clinical trial studies the following conditions: Insomnia.

What interventions are being tested in trial NCT02756390?

The interventions under investigation include: Sleep Hygiene (BEHAVIORAL), CBTI-CS (BEHAVIORAL), CBTI-CS via Telehealth (BEHAVIORAL).

Who is sponsoring clinical trial NCT02756390?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02756390 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02756390's enrollment target sits among peer trials

56 95th of 151 higher than 54 of 151 other Insomnia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02287428 · 56 participants · Phase 1

    Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

  • NCT02923011 · 56 participants · Phase 3

    Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas

  • NCT02935283 · 56 participants

    Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders

  • NCT03375866 · 56 participants · NA

    Effects of Mixed Nut Consumption on Satiety and Weight Management

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02756390, the US trial registry maintained by the National Library of Medicine. NCT02756390 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.